Build a comprehensive solution in the field of respiratory medicine, from drugs to medical devices! CF PHARMTECH (02652) successfully completes the first clinical trial of bronchial valves (EBV) in patients with severe emphysema.

On April 27, 2026, CF PHARMTECH (02652) announced a key clinical advancement in the field of respiratory intervention medical devices: in a clinical trial for treating severe emphysema, the company's independently developed Endobronchial Valve (EBV) showed promising treatment results in the first patient, who has now successfully completed clinical observation and been discharged. This development signifies the company's achievement in establishing a systematic pipeline layout from inhaled drugs to interventional devices, further solidifying its comprehensive strength in the field of respiratory disease solutions. EBV: Providing a minimally invasive treatment option for COPD emphysema The Endobronchial Valve (EBV) is an Innovative Medical Management device strategically deployed by CF PHARMTECH for the minimally invasive treatment of Chronic Obstructive Pulmonary Disease (COPD) emphysema. Emphysema is a progressive, irreversible lung disease characterized by destruction of alveolar structure, lung over-inflation, and gas retention, severely impacting the quality of life for patients. Through minimally invasive bronchoscopy, EBV is implanted in the most severely damaged lung lobe airway, causing the over-inflated lung tissue to gradually collapse, improving healthy lung function, and offering a new treatment option for patients with severe emphysema who respond poorly to drug therapy. The successful completion of the first patient in the clinical trial treatment and discharge is an important milestone in the development process of the EBV project, accumulating valuable experience for the advancement of future clinical trials. Perfecting the respiratory disease pipeline, implementing a "drug + device" synergistic strategy As a comprehensive innovative pharmaceutical company focused on inhalation formulations and respiratory system disease research, production, and commercialization, CF PHARMTECH has established a product matrix covering multiple diseases such as asthma, COPD, allergic rhinitis, etc. The company possesses five core technology platforms in particle engineering, device design, product performance evaluation, clinical development, and process engineering, supporting the simultaneous development of innovative drugs and devices. The steady progress of the EBV project allows the company to extend from inhaled drug therapy to interventional device therapy, establishing a comprehensive management solution covering mild to moderate disease drug intervention to severe or critical disease device intervention, further strengthening its comprehensive layout in the field of respiratory disease treatment. Filling the unmet clinical needs of severe emphysema The global and Chinese respiratory disease market space is vast. COPD is one of the common chronic respiratory diseases in China, with a large population of emphysema patients and limited existing drug treatment options, highlighting significant unmet clinical needs. As an interventional treatment method, EBV has been recommended in international clinical guidelines and is expected to bring tangible clinical benefits to patients with severe emphysema. Continuously driving innovation to promote respiratory health CF PHARMTECH will continue to efficiently advance clinical research projects like EBV, while deepening the collaborative research and development of inhalation formulations and innovative devices, dedicated to providing more and better treatment options for patients with respiratory system diseases. By focusing on respiratory health and caring for life, the company aims to continuously improve the respiratory health industry in China.